Less Ads, More Data, More Tools Register for FREE

Edison

Edison's team of 50-plus analysts produces award-winning, tier one-standard equity research and investment analysis. In 2023, our international coverage includes daily in-depth scrutiny of over 225 stocks, connecting targeted investor groups across institutions, family offices, wealth managers and retail investors insight into our clients.

Edison specialises in expanding the global capital markets' understanding of our clients' investment cases. We do this through our unique combination of integrated services under the banner Complete IR which enhances our award-winning research with bespoke digital marketing services and investor relations engagement.
Date TIDM Title
09-Oct-24SPA1Spatial - Federal-level win in the US
08-Oct-24IRLAB Therapeutics - IRL757 progress prompts $2.5m milestone payment
08-Oct-240LSECI Games - Strategic roadmap to 2028
07-Oct-24Actinogen Medical - Funding in place to complete XanaMIA Phase IIb
07-Oct-24GAWGames Workshop Group - Sigmar the fourth
07-Oct-24Datatec - Encouraging H1 across all divisions
04-Oct-24CARDCard Factory - Confident on FY25 outlook
04-Oct-24IMMX.USImmix Biopharma - US CAR-T trial progresses to dose expansion
03-Oct-24HUWHelios Underwriting - Strategic shift from growth to consolidation
03-Oct-24HOTHenderson Opportunities Trust - Taking AIM at the opportunity
03-Oct-24IRLAB Therapeutics - IRL757 starts strong in Phase I
03-Oct-24TFG.AMTetragon Financial Group - Tetragon maintains its investing pace
02-Oct-24Cereno Scientific - CS1 shines in Phase IIa PAH trial
02-Oct-24GRIDGresham House Energy Storage Fund - Rising revenues and big plans f...
02-Oct-24TPTTopps Tiles - Slight sequential improvement in Q424
02-Oct-24INPPInternational Public Partnerships - FHSP partial realisation with £...
02-Oct-240RDBOryzon Genomics - FDA aligns on Phase III BPD plans
01-Oct-24GRGGreggs - Good Q324 on strong comparative
01-Oct-24SEITSDCL Energy Efficiency Income Trust - Portfolio growth ahead of budget
01-Oct-24IRLAB Therapeutics - Pirepemat Phase IIb trial completes enrolment
01-Oct-24RGLRegional REIT - A clear strategy to realise value
30-Sep-24AFT Pharmaceuticals - Maxigesic IV reaches the Chinese shores
30-Sep-24KGEI.USKolibri Global Energy - Termination of coverage
30-Sep-24NNDM.USNano Dimension - Scaling up
27-Sep-24PAFPan African Resources - Analysing H224 and looking forward to FY25
26-Sep-24GRPGreencoat Renewables - Efficient capital allocation and increasing...
26-Sep-24HINTHenderson International Income Trust - Buying into the rapid spread...
25-Sep-24IHRImpact Healthcare REIT - Successful turnaround
25-Sep-24AUSCabrdn UK Smaller Companies Growth Trust - Solid relative performanc...
25-Sep-24AXS.AMAccsys Technologies - Tricoya project to be discontinued